List of articles with "Amgen"

Amgen at 2026 Global Healthcare

Amgen at 2026 Global Healthcare

United States Innovation Healthcare Conference Amgen Thousand Oaks
Amgen Dividend Update

Amgen Dividend Update

USA Dividend biotechnology Amgen Thousand Oaks
Amgen at TD Cowen Conference

Amgen at TD Cowen Conference

United States Amgen Thousand Oaks Health Care TD Cowen
Amgen's UPLIZNA® Approved

Amgen's UPLIZNA® Approved

None Amgen Myasthenia Gravis UPLIZNA
UPLIZNA® Approved

UPLIZNA® Approved

None Amgen Myasthenia Gravis UPLIZNA
Amgen's UPLIZNA® Approved

Amgen's UPLIZNA® Approved

Amgen Thousand Oaks Czech Republic Myasthenia Gravis UPLIZNA
Amgen UPLIZNA Approval

Amgen UPLIZNA Approval

None Amgen Myasthenia Gravis UPLIZNA
UPLIZNA® Approved

UPLIZNA® Approved

None Amgen Myasthenia Gravis UPLIZNA
Approval of UPLIZNA®

Approval of UPLIZNA®

None Amgen Myasthenia Gravis UPLIZNA
UPLIZNA® Approved

UPLIZNA® Approved

None Amgen Myasthenia Gravis UPLIZNA
UPLIZNA® Approval

UPLIZNA® Approval

United Kingdom Amgen Thousand Oaks GMG UPLIZNA®
Amgen's 2025 Growth Report

Amgen's 2025 Growth Report

United States financial results revenue growth Amgen Thousand Oaks
Ro and Amgen's Research

Ro and Amgen's Research

USA New York Amgen GLP-1 Ro
Amgen Presents at Conference

Amgen Presents at Conference

United States Healthcare Conference J.P. Morgan Amgen Thousand Oaks
Amgen Acquires Dark Blue Therapeutics

Amgen Acquires Dark Blue Therapeutics

United Kingdom Oxford Acute Myeloid Leukemia Amgen Dark Blue Therapeutics
Amgen Acquires Dark Blue

Amgen Acquires Dark Blue

United States oncology Amgen Thousand Oaks Dark Blue Therapeutics
Amgen's Commitment to Affordable Medicines

Amgen's Commitment to Affordable Medicines

United States healthcare Amgen Thousand Oaks Drug Pricing
UPLIZNA® Approved

UPLIZNA® Approved

United States Amgen Thousand Oaks Myasthenia Gravis UPLIZNA
Amgen 2026 Dividend

Amgen 2026 Dividend

United States Dividend Amgen Thousand Oaks NASDAQ:AMGN
Amgen and LASEC Partnership

Amgen and LASEC Partnership

USA Los Angeles Amgen World Cup 2026
IMDELLTRA® FDA Approval

IMDELLTRA® FDA Approval

Amgen Thousand Oaks SCLC IMDELLTRA
Repatha® Lowers CV Event Risk

Repatha® Lowers CV Event Risk

None Amgen Repatha PCSK9 Inhibitor
Amgen Q3 2025 Results

Amgen Q3 2025 Results

USA Amgen Thousand Oaks, California Repatha Otezla
Amgen's Dividend Announcement

Amgen's Dividend Announcement

United States Dividend biotechnology Amgen Thousand Oaks
Repatha Phase 3 Results

Repatha Phase 3 Results

United States New Orleans Amgen Repatha Cardiovascular Trials
TEZSPIRE® Approval

TEZSPIRE® Approval

United States Amgen Thousand Oaks TEZSPIRE Allergy
AmgenNow Program

AmgenNow Program

USA Amgen Thousand Oaks Repatha AmgenNow
Repatha Trial Results

Repatha Trial Results

USA Amgen Thousand Oaks Repatha VESALIUS-CV
Amgen’s $650M Expansion

Amgen’s $650M Expansion

USA biopharmaceuticals Amgen Thousand Oaks USA manufacturing
Rocatinlimab Phase 3 Results

Rocatinlimab Phase 3 Results

USA Amgen Thousand Oaks Kyowa Kirin Rocatinlimab
Amgen's Major Investment

Amgen's Major Investment

United States Innovation Amgen Thousand Oaks Biopharmaceutical
Veeva and Amgen Collaborate

Veeva and Amgen Collaborate

USA Veeva Systems Barcelona Clinical Trials Amgen
Veeva and Amgen Collaboration

Veeva and Amgen Collaboration

USA Veeva Systems Barcelona Clinical Trials Amgen
Veeva and Amgen Collaboration

Veeva and Amgen Collaboration

USA Veeva Systems Barcelona Clinical Trial Amgen
Veeva and Amgen Partnership

Veeva and Amgen Partnership

USA Veeva Systems Clinical Trials Amgen Pleasanton
Veeva and Amgen Collaboration

Veeva and Amgen Collaboration

Spain Veeva Systems Barcelona Clinical Trials Amgen
Repatha Approval Expanded

Repatha Approval Expanded

United States Amgen Thousand Oaks Repatha LDL Cholesterol
Amgen Second Quarter 2025

Amgen Second Quarter 2025

USA Amgen Thousand Oaks Repatha TAVNEOS
Amgen's Q3 2025 Dividend

Amgen's Q3 2025 Dividend

United States Dividend biotechnology Amgen Thousand Oaks
Amgen's Bemarituzumab Trial Results

Amgen's Bemarituzumab Trial Results

United States Amgen Thousand Oaks gastric cancer Bemarituzumab
Promising Results of MariTide

Promising Results of MariTide

United States California MariTide Amgen Obesity Treatment
Amgen's MariTide Data

Amgen's MariTide Data

United States Chicago MariTide Amgen Type 2 Diabetes
Barry Sanders & Cholesterol

Barry Sanders & Cholesterol

USA Amgen Thousand Oaks Barry Sanders Cholesterol
IMDELLTRA® Breakthrough

IMDELLTRA® Breakthrough

United States Amgen Thousand Oaks small cell lung cancer IMDELLTRA®
Amgen Q1 2025 Results

Amgen Q1 2025 Results

None Amgen Repatha IMDELLTRA
Amgen Expands in Ohio

Amgen Expands in Ohio

United States Manufacturing Ohio Amgen Ohio Expansion
UPLIZNA Approved for IgG4-RD

UPLIZNA Approved for IgG4-RD

United States Las Vegas Amgen UPLIZNA IgG4-RD
IMDELLTRA® and SCLC

IMDELLTRA® and SCLC

USA Amgen Thousand Oaks SCLC IMDELLTRA
Rocatinlimab Success

Rocatinlimab Success

USA Amgen Thousand Oaks Kyowa Kirin Rocatinlimab
Rocatinlimab Phase 3 Insights

Rocatinlimab Phase 3 Insights

USA Amgen Thousand Oaks Kyowa Kirin Rocatinlimab

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.